Pharmaceutical manufacturing handbook regulations and quality

Tài liệu dược phẩm

PHARMACEUTICAL MANUFACTURING HANDBOOK

Regulations and

Quality

SHAYNE COX GAD, PH.D., D.A.B.T.

Gad Consulting Services

Cary, North Carolina

A JOHN WILEY & SONS, INC., PUBLICATION

PHARMACEUTICAL MANUFACTURING HANDBOOK

Regulations and

Quality

PHARMACEUTICAL MANUFACTURING HANDBOOK

Regulations and

Quality

SHAYNE COX GAD, PH.D., D.A.B.T.

Gad Consulting Services

Cary, North Carolina

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2008 by John Wiley & Sons, Inc All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form

or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee

to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com Requests to the Publisher for permission should

be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken,

NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts

in preparing this book, they make no representations or warranties with respect to the accuracy

or completeness of contents of this book and specifi cally disclaim any implied warranties of

merchantability or fi tness for a particular purpose No warranty may be created or extended by sales representatives or written sales materials The advice and strategies contained herein may not be suitable for your situation You should consult with a professional where appropriate Neither the publisher nor author shall be liable for any loss of profi t or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States

at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats Some content that appears in print may not be available in electronic formats For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data is available.

ISBN: 978-0-470-25959-7

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

CONTRIBUTORS

v

Emmanuel O Akala, Department of Pharmaceutical Sciences, School of Pharmacy,

Howard University, Washington, DC, Effect of Packaging on Stability of Drugs and Drug Products

Giuseppe Alibrandi, Universit à di Messina, Messina, Italy, Alternative Accelerated

Methods for Studying Drug Stability: Variable - Parameter Kinetics

Edward R Arling, Amgen, Inc., Thousand Oaks, California, Creating and Managing

a Quality Management System

Christina Bartmann, Medical University of Graz, Graz, Austria, GMP - Compliant

Propagation of Human Multipotent Mesenchymal Stromal Cells

James M Barquest, Ground Zero Pharmaceuticals, Inc., Irvine, California, Role of

Quality Systems and Audits in Pharmaceutical Manufacturing Environment

Denise Bohrer, Chemistry Department, Universidade Federal de Santa Maria,

Santa Maria, Brazil, Origin of Contamination

Chung Chow Chan, Azopharma Contract Pharmaceutical Services, Miramar,

Florida, Analytical Method Validation: Principles and Practices

Robert P Cogdill, Duquense University Center for Pharmaceutical Technology,

Pittsburgh, Pennsylvania, Case for Process Analytical Technology: Regulatory and Industrial Perspectives

Marc De Loose, Institute for Agricultural and Fisheries Research (ILVO), Scientifi c

Institute for the Flemish Community, Merelbeke, Belgium, Analytical Method Validation and Quality Assurance

Katherine V Domenick, Training and Communications Group, Inc., Berwyn,

Pennsylvania, Personnel Training in Pharmaceutical Manufacturing

vi CONTRIBUTORS

Michelle E Dowling, Amgen, Inc., Thousand Oaks, California, Creating and

Man-aging a Quality Management System

L Antonio Est é vez, University of Puerto Rico, Mayag ü ez, Puerto Rico, Drug Stability

D.C Ferreira, Faculty of Pharmacy, University of Porto, Porto, Portugal,

Pharma-ceutical Manufacturing Validation Principles

Alvin Fox, University of South Carolina, Columbia, South Carolina, tion of Markers for Gram - Negative and Gram - Positive Endotoxins in Work Environment and as Contaminants in Pharmaceutical Products Using Gas Chromatography – Tandem Mass Spectrometry

Quantita-Paul A Frankel, Amgen, Inc., Thousand Oaks, California, Creating and Managing

a Quality Management System

David A Gallup, Training and Communications Group, Inc., Berwyn, Pennsylvania,

Personnel Training in Pharmaceutical Manufacturing

Srinivas Ganta, University of Auckland, Auckland, New Zealand, Scale - Up and

Postapproval Changes (SUPAC) Regulations

Sanjay Garg, University of Auckland, Auckland, New Zealand, Scale - Up and

Post-approval Changes (SUPAC) Regulations

Marge Gillis, Training and Communications Group, Inc., Berwyn, Pennsylvania,

Personnel Training in Pharmaceutical Manufacturing

James R Harris, James Harris Associates, Inc., Durham, North Carolina, Good

Manufacturing Practices (GMP) and Related FDA Guidelines

Ashley John, New Jersey Institute of Technology, Newark, New Jersey, Analytical

and Computational Methods and Examples for Designing and Controlling Total Quality Management Pharmaceutical Manufacturing Systems

Herman Lam, Wild Crane Horizon, Inc., Scarborough, Ontario, Canada, Validation

of Laboratory Instruments

Marko N ä rhi, Helsinki University of Technology, Helsinki, Finland, National GMP

Regulations and Codes and International GMP Guides and Guidelines: spondences and Differences

Corre-Kenneth J Nolan, Nolan & Auerbach, Fort Lauderdale, Florida, Enforcement of

Good Manufacturing Practices

Katrina Nordstr ö m, Helsinki University of Technology, Helsinki, Finland, National

GMP Regulations and Codes and International GMP Guides and Guidelines: Correspondences and Differences

Nazario D Ramirez - Beltran, University of Puerto Rico, Mayag ü ez, Puerto Rico,

Drug Stability

Gregory N Ranky, Public Research University of New Jersey, Newark, New Jersey,

Analytical and Computational Methods and Examples for Designing and ling Total Quality Management Pharmaceutical Manufacturing Systems

Control-CONTRIBUTORS vii

Paul G Ranky, New Jersey Institute of Technology, Newark, New Jersey, Analytical

and Computational Methods and Examples for Designing and Controlling Total Quality Management Pharmaceutical Manufacturing Systems

Richard G Ranky, New Jersey Institute of Technology, Newark, New Jersey,

Ana-lytical and Computational Methods and Examples for Designing and Controlling Total Quality Management Pharmaceutical Manufacturing Systems

Andreas Reinisch, Medical University of Graz, Graz, Austria, GMP - Compliant Propagation of Human Multipotent Mesenchymal Stromal Cells

Harry Rodriguez, Cordis LLC, a Johnson & Johnson Company, San Juan, Puerto

Rico, Drug Stability

Yves Roggo, F Hoffmann - La Roche, Ltd., Basel, Switzerland, Process Analytical

Technology; Chemical Imaging and Chemometrics: Useful Tools for Process lytical Technology

Ana-Eva Rohde, Medical University of Graz, Graz, Austria, GMP - Compliant

Propaga-tion of Human Multipotent Mesenchymal Stromal Cells

B Saramento, Faculty of Pharmacy, University of Porto, Porto, Portugal,

Pharma-ceutical Manufacturing Validation Principles

Katharina Schallmoser, Medical University of Graz, Graz, Austria, GMP - Compliant Propagation of Human Multipotent Mesenchymal Stromal Cells

Puneet Sharma, University of Auckland, Auckland, New Zealand, Scale - Up and

Postapproval Changes (SUPAC) Regulations

Evan B Siegel, Ground Zero Pharmaceuticals, Inc., Irvine, California, Role of Quality Systems and Audits in Pharmaceutical Manufacturing Environment

E.B Souto, Free University of Berlin, Berlin, Germany; Faculty of Pharmacy,

University of Porto, Porto, Portugal, Pharmaceutical Manufacturing Validation Principles

Dirk Strunk, Medical University of Graz, Graz, Austria, GMP - Compliant

Propaga-tion of Human Multipotent Mesenchymal Stromal Cells

Michel Ulmschneider, F Hoffman - La Roche, Ltd., Basel, Switzerland, Process

Ana-lytical Technology; Chemical Imaging and Chemometrics: Useful Tools for Process Analytical Technology

Isabel Taverniers, Institute for Agricultural and Fisheries Research (ILVO),

Scien-tifi c Institute for the Flemish Community, Merelbeke, Belgium, Analytical Method Validation and Quality Assurance

Erik Van Bockstaele, Institute for Agricultural and Fisheries Research (ILVO),

Scientifi c Institute for the Flemish Community, Merelbeke, Belgium, Analytical Method Validation and Quality Assurance

T Vasconcelos, Laboratory of Pharmaceutical Development, BIAL, Mamede do

Coronado, Portugal; Faculty of Pharmacy, University of Porto, Porto, Portugal,

Pharmaceutical Manufacturing Validation Principles

viii CONTRIBUTORS

Ranga Velagaleti, BASF Corporation, Florham Park, New Jersey, Microbiology of

Nonsterile Pharmaceutical Manufacturing; Stability and Shelf Life of tical Products

Pharmaceu-Andrew A Webster, McWhorter School of Pharmacy, Birmingham, Alabama,

Phar-maceutical Product Stability

Jyh - hone Wang, University of Rhode Island, Kingston, Rhode Island, Quality Process Improvement

CONTENTS

PREFACE xiii

SECTION 1 GOOD MANUFACTURING PRACTICES (GMP) AND

1.1 Good Manufacturing Practices (GMPs) and Related FDA

Guidelines 3

James R Harris

1.2 Enforcement of Current Good Manufacturing Practices 45

Kenneth J Nolan

1.3 Scale-Up and Postapproval Changes (SUPAC) Regulations 67

Puneet Sharma, Srinivas Ganta, and Sanjay Garg

1.4 GMP-Compliant Propagation of Human Multipotent Mesenchymal

Eva Rohde, Katharina Schallmoser, Christina Bartmann, Andreas Reinisch,

and Dirk Strunk

SECTION 2 INTERNATIONAL REGULATIONS OF GOOD

2.1 National GMP Regulations and Codes and International GMP

Guides and Guildelines: Correspondences and Differences 119

Marko Närhi and Katrina Nordström

Paul G Ranky, Gregory N Ranky, Richard G Ranky, and Ashley John

3.2 Role of Quality Systems and Audits in Phatmaceutical

Evan B Siegel and James M Barquest

3.3 Creating and Managing a Quality Management System 239

Edward R Arling, Michelle E Dowling, and Paul A Frankel

4.1 Case for Process Analytical Technology: Regulatory and Industrial

Perspectives 313

Robert P Cogdill

Michel Ulmschneider and Yves Roggo

4.3 Chemical Imaging and Chemometrics: Useful Tools for Process

Yves Roggo and Michel Ulmschneider

5.1 Personnel Training in Pharmaceutical Manufacturing 435

David A Gallup, Katherine V Domenick, and Marge Gillis

SECTION 6 CONTAMINATION AND CONTAMINATION

CONTROL 455

Denise Bohrer

6.2 Quantitation of Markers for Gram-Negative and Gram-Positive

Endotoxins in Work Environment and as Contaminants in

Pharmaceutical Products Using Gas Chromatography–Tandem

6.3 Microbiology of Nonsterile Pharmaceutical Manufacturing 543

Ranga Velagaleti

CONTENTS xi

7.1 Stability and Shelf Life of Pharmaceutical Products 559

Ranga Velagaleti

Nazario D Ramirez-Beltran, Harry Rodriguez, and L Antonio Estévez

7.3 Effect of Packaging on Stability of Drugs and Drug Products 641

8.1 Analytical Method Validation: Principles and Practices 727

Chung Chow Chan

8.2 Analytical Method Validation and Quality Assurance 743

Isabel Taverniers, Erik Van Bockstaele, and Marc De Loose

8.4 Pharmaceutical Manufacturing Validation Principles 811

E B Souto T Vasconcelos D C Ferreira, and B Sarmento

INDEX 839

PREFACE

This Handbook of Manufacturing: Regulations and Quality focuses on all regulatory

aspects and requirements that govern how drugs are produced for evaluation (and, later, sale to and use in) humans The coverage ranges from what the issues are at the early stages (when the amounts are small and the materials of limited sophistica-tion) up to until the issue is reproducibly and continuously making large volumes

of a highly sophisticated manufactured product These 25 chapters cover the full range from preformulation of a product (the early exploratory work that allows us

to understand how to formulate and deliver the drug) to identifi cation of sources

of contamination and assessment of stability

The Handbook of Manufacturing: Regulations and Quality seeks to cover the

entire range of available approaches to satisfying the wide range of regulatory requirements for making a highly defi ned product that constitutes a successful new drug and how to do so in as effective and as effi cient a manner as possible

Thanks to the persistent efforts of Michael Leventhal, these 25 chapters, which are written by leading practitioners in each of these areas, provide coverage of the primary approaches to the fundamental regulatory challenges that must be over-come to manufacture successfully a deliverable and stable new drug

GOOD MANUFACTURING PRACTICES ( GMP ) AND OTHER FDA GUIDELINES SECTION 1

1.1

Pharmaceutical Manufacturing Handbook: Regulations and Quality, edited by Shayne Cox Gad

Copyright © 2008 John Wiley & Sons, Inc.

1.1.1 FDA Regulations: Real and Imagined

1.1.2 21 CFR 210 and 211: Current Good Manufacturing Practice for Finished Pharmaceuticals

1.1.3 Guidance for Industry: Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations

1.1.3.1 CGMPS and the Concepts of Modern Quality Systems

1.1.3.2 Quality Systems Model

1.1.4 Guidance for Industry: PAT — Framework for Innovative Pharmaceutical ment, Manufacturing, and Quality Assurance

1.1.7.1 Validation of Batch Powder Mix Homogeneity

1.1.7.2 Verifi cation of Manufacturing Criteria

1.1.8 Guidance for Industry: Immediate - Release Solid Oral Dosage Forms Scale - Up and Postapproval Changes (SUPAC) — Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation

1.1.9 Other GMP - Related Guidance Documents

4 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

1.1.1 FDA REGULATIONS: REAL AND IMAGINED

A regulation is a law In the United States, all federal laws have been arranged or

codifi ed in a manner that makes it easier to fi nd a specifi c law The Code of Federal Regulations (CFR) is a compilation of all federal laws published in the Federal Register by the executive departments and agencies of the federal government This

code is divided into 50 titles which represent broad areas of federal regulation Each title is further divided into chapters The chapters are then subdivided into parts covering specifi c regulatory areas Changes and additions are fi rst published in the

Federal Register Both the coded law and the Federal Register must be used to

deter-mine the latest version of any rule All food - and drug - related laws are contained

in Title 21 of the CFR Each title of the CFR is updated annually Title 21 is updated

as of April 1 of each year

Because virtually all of the drug regulations are written to state what should be done but do not tell how to do it, the Food and Drug Administration (FDA) also publishes guidance documents These documents are intended to provide precisely

what the name implies — guidance In this context, guidance documents are not law and do not bind the FDA or the public Manufacturers are not required to use the

techniques or approaches appearing in the guidance document In fact, FDA resentatives have repeatedly stated that the regulations were not written to suggest how something should be done in order to encourage innovation While following the recommendations contained in the guidance documents will probably assure acceptance (agency philosophy and interpretation may have changed since the guid-ance document was published), other approaches are encouraged No matter how they choose to proceed, manufacturers should be prepared to show that their methods achieve the desired results

A method used by the FDA to “ fl oat ” new ideas is to discuss them at industry gatherings such as FDA - sponsored seminars or meetings of industry groups such as the Pharmaceutical Manufacturers Association (PMA), the Parenteral Drug Asso-ciation (PDA), and the International Society of Pharmaceutical Engineering (ISPE) Again, it must be remembered that while these comments refl ect current FDA thinking, they are simply thoughts and recommendations They are not law

Several industry groups also publish comments, guidelines, and so on, that put forth current thinking of the group writing the document These publications are interesting and often bring out valuable information However, it is important to

remember that these publications are not regulations or even offi cial guidance ments If a fi rm chooses to follow the recommendations of such documents, they are

docu-probably following good advice However, since the advice comes from a nonoffi cial source, fi rms should still be prepared to defend their actions with good scientifi c reasoning

1.1.2 21 CFR 210 AND 211: CURRENT GOOD MANUFACTURING

PRACTICE FOR FINISHED PHARMACEUTICALS

Parts 210 and 211 of CFR Title 21 are the laws defi ning good manufacturing tices for fi nished pharmaceutical products All manufacturers must follow these regulations in order to market their products in the United States When a fi rm fi les

prac-an application to market a product in the United States through a New Drug cation (NDA), abbreviated NDA, (ANDA), Biological License Application (BLA),

Appli-CURRENT GOOD MANUFACTURING PRACTICE 5

or other product application, one of the last steps in approving the application is a preapproval inspection of the manufacturing facility A major purpose of this inspec-tion is to assure adherence to the GMP regulations Preapproval inspections are a part of every application approval Thus, if a fi rm has 10 applications pending, it should expect 10 inspections The fact that the manufacturing facility has already been inspected will not alter the need for another inspection

The FDA also has the right to visit and inspect any manufacturing facility that produces a product or products sold in the United States Such inspections are unan-nounced A manufacturer must admit an inspector when he or she appears at that facility and must do so without undue delay

GMP requirements for manufacturers of pharmaceutical dosage forms are

dis-cussed below This information should not be considered to be an exact statement

of the law We have attempted to show intent and, occasionally, add some comments that will clarify how that particular regulation is interpreted For precise wording of

a regulation, refer to the CFR and then check the Federal Register to determine if

there have been any changes since the last update

prod-of drugs by virtue prod-of their intended use

Organization and Personnel

1 Responsibilities of quality control unit

(a) A quality control unit must be a part of the facility organization

(b) This unit must be given responsibility and authority to approve or reject all components, drug product containers, closures, process materials, packaging material, labeling, and drug products, and the authority to review production records

(c) Adequate laboratory facilities for testing and approval or rejection of the above listed materials must be available

(d) The quality control unit is responsible for approving or rejecting all dures or specifi cations that impact on the identity, strength, quality, and purity

proce-of the drug product

(e) Responsibilities and procedures applicable to the quality control unit must

be written and these procedures must be followed

2 Personnel qualifi cations

(a) Every person involved in the manufacture, processing, packing, or holding of

a drug product must have education, training, and experience that enable that individual to perform their duties Employees must be trained in the particular operations that they perform and in Current GMPs (CGMPs) The GMP training must be conducted by qualifi ed individuals and with suffi cient frequency to assure that workers remain familiar with the requirements applicable to them

6 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

(b) Persons responsible for supervision must have the education, training, and experience to perform their assigned functions in such a manner as to assure that the drug product has the safety, identity, strength, quality, and potency that it is represented to possess

(c) There must be an adequate number of qualifi ed personnel to perform the needed tasks

3 Personnel responsibilities

(a) Personnel shall wear clean clothing appropriate for the duties they perform Protective apparel must be worn as necessary

(b) Personnel shall practice good sanitation and health habits

(c) Only personnel authorized by supervisory personnel shall enter those areas designated as limited - access areas

(d) Any worker considered to have an apparent illness or open lesions that may adversely affect safety or quality of drug products shall be excluded from direct contact with product, components, or containers

4 Consultants that advise on the manufacture, processing, packing, or holding of drug products must have suffi cient education, training, and experience to advise

on the subject for which they are retained The manufacturer must maintain records of name, address, and qualifi cations of any consultants and the type of service they provide

Buildings and Facilities

1 Design and construction features

(a) Buildings should be of suitable size, construction location to facilitate ing, maintenance, and proper operations

(b) Space should be adequate for the orderly placement of equipment and rials to prevent mix - ups between different components, drug product con-tainers and closures, labeling, in - process materials, or drug products and to prevent contamination

(c) The movement of components and product through the building must be designed to prevent contamination

(d) Operations should be performed within specifi cally defi ned areas having adequate control systems to prevent contamination or mix - ups during each

of the following procedures:

(i) Receipt, identifi cation, storage, and withholding from use of nents, drug product containers, closures, and labeling, pending the appropriate sampling, testing, and release for manufacturing or packaging

(ii) Holding rejected materials listed in (a) above

(iii) Storage of released components, drug product containers, closures, and labeling

(iv) Storage of in - process materials

(v) Manufacturing and processing operations

(vi) Packaging and labeling operations

(vii) Quarantine storage before release of drug products

(viii) Storage of drug products after release

(ix) Control and laboratory operations

CURRENT GOOD MANUFACTURING PRACTICE 7

(x) Aseptic processing, which includes:

(1) Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable

(2) Temperature and humidity controls

(HEPA) fi lters under positive pressure regardless of whether fl ow

is laminar or nonlaminar

(4) A system for monitoring environmental conditions

(5) A system for cleaning and disinfecting the room and equipment to produce aseptic conditions

(6) A system for maintaining any equipment used to control the aseptic conditions

(e) Operations relating to the manufacture, processing, and packing of penicillin must be performed in facilities separate from those used for other drug

products for humans Note : For all purposes of these GMP regulations, the

FDA considers cephalosporins to be penicillin

2 Adequate lighting should be provided in all areas

3 Heating, ventilation, and air conditioning (HVAC)

(a) Adequate ventilation is required in all areas

(b) Equipment for adequate control over air pressure, microorganisms, dust, humidity, and temperature must be provided when appropriate for the manu-facture, processing, packing, or holding of a drug product

(c) When appropriate, air supplied to production areas should be fi ltered to avoid any possibility of contamination or cross - contamination

(d) Air - handling systems for the manufacture, processing, and packing of lin shall be completely separate from those for other drug products for humans

4 Plumbing

(a) Potable water should be supplied in a continuous positive - pressure system free from defects that could contribute to contamination of any drug product

(b) Potable water must meet the standards prescribed in the Environmental Protection Agency (EPA) Primary Drinking Water Regulations defi ned in

40 CFR Part 141

(c) Drainage must be of adequate size Where connected directly to a sewer, an air break or other suitable mechanical device must be provided to prevent back - siphonage

5 Sewage, trash, and other refuse in and from the building and immediate premises must be disposed of in a safe and sanitary manner

6 Adequate washing facilities should be provided This is to include hot and cold water, soap or detergent, air driers or single - service towels, and clean toilet facili-ties easily accessible to all work areas

7 Sanitation

(a) Any building used for manufacture, processing, packing, or holding of a drug product should be maintained in a clean and sanitary condition Such buildings should be free of infestation by rodents, birds, insects, and other vermin (b) Trash and organic waste matter should be held and disposed of in a timely and sanitary manner

8 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

(c) Written procedures assigning responsibility for sanitation and describing in suffi cient detail the cleaning schedules, methods, equipment, and materials

to be used in cleaning the buildings and facilities are required Such dures must be followed

(d) Written procedures for use of suitable rodenticides, insecticides, fungicides, fumigating agents, and cleaning and sanitizing agents are required and must

be followed These written procedures should be designed to prevent the contamination of equipment, components, product containers, closures, pack-aging, labeling materials, or drug products Agent may not be used unless registered and used in accordance with the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C 135)

(e) All sanitation procedures apply equally to contractors or temporary ees as to regular employees

8 All buildings used for GMP - related purposes must be maintained in a good state

of repair

Equipment

1 Equipment should be of appropriate design, adequate size, and suitably located

to facilitate operations for its intended use and for cleaning and maintenance

2 Equipment construction

(a) Equipment should be constructed so that surfaces that contact components,

in - process materials, or drug products should not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond offi cial or other established requirements

(b) Any substance required for operation such as lubricants or coolants shall not come into contact with drug products, containers, and so on, so as to alter the safety, identity, strength, quality, or purity of the drug product beyond established requirements

3 Equipment cleaning and maintenance

appropriate intervals to prevent malfunctions or contamination that would alter the drug product beyond the offi cial requirements

maintenance of equipment and utensils used in the processing of a drug product These procedures must include but are not limited to the following:

(i) Assignment of responsibility for cleaning and maintaining equipment (ii) Maintenance and cleaning schedules, including sanitizing schedules if appropriate

(iii) A suffi ciently detailed description of the methods, equipment, and materials used in cleaning and maintenance operations and the methods

of disassembling and reassembling equipment as a part of cleaning and maintenance

(iv) Removal or obliteration of previous batch identifi cation

(v) Protection of clean equipment from contamination prior to use (vi) Inspection of equipment for cleanliness immediately before use

CURRENT GOOD MANUFACTURING PRACTICE 9

(vii) Records should be kept of maintenance, cleaning, sanitizing, and tion of all processing equipment

4 Automatic, mechanical, and electronic equipment

(a) All such equipment, including computers or related systems that will perform

a function to be used in any GMP - related activity, must be routinely brated, inspected, or checked according to a written program designed to assure proper performance Written records must be maintained for all such activities

(b) Appropriate controls should be exercised to assure that changes in master production and control records or other similar records are made only by authorized personnel Input to and output from such systems should be checked for accuracy

A backup fi le of data entered into a computer - related system must be maintained except where certain data such as calculations performed in con-nection with laboratory analysis are eliminated by computerization or other automated processes In this situation, a written record of the program should

be maintained along with validation data

5 Filters for liquid fi ltration used as a part of the manufacture, processing, or packing of injectable drug products intended for human use must not release

fi bers into such products Fiber - releasing fi lters may not be used unless it is not possible to manufacture the product without the use of such a fi lter In this situ-

after the fi ber - releasing fi ltration Use of an asbestos - containing fi lter is sible only upon submission of proof to the appropriate FDA bureau that use of

permis-a non - fi ber - relepermis-asing fi lter will compromise the spermis-afety or effectiveness of the drug product

Control of Components and Drug Product Containers and Closures

ers, closures, and so on

(b) All components listed above must be handled and stored in a manner that will prevent contamination

(c) Bagged or boxed components should be stored off the fl oor Spacing should allow cleaning and inspection

(d) Every container of components must be identifi ed with a distinctive code or lot number for each receival of that product Even if the next receival is the same vendor lot number, it must be a new identifying number by the phar-maceutical manufacturer Each lot must be appropriately identifi ed as to its status (quarantined, approved, or rejected)

10 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

2 Receipt and storage of untested components

(a) Upon receipt each container of components must be visually examined for appropriate labeling and any damage or contamination to the component container

(b) Components must be stored under quarantine until they have been tested as appropriate and released for use

3 Testing and approval or rejection of components

(a) Each lot of components shall be withheld from use until it has been sampled, tested, and released by the quality control unit

(b) Representative samples must be taken from every receival of every nent The number or amount of component to be sampled should be based

compo-on compcompo-onent appearance, statistical ccompo-onfi dence levels, the past history of the supplier, and the quantity needed to analyze and reserve samples if required

(c) Sampling procedures

(i) The component containers should be cleaned where necessary

(ii) The containers should be opened, sampled, and resealed in a manner designed to prevent contamination of the sample and remaining con-tents of the container

(iii) If appropriate, sterile equipment and aseptic sampling techniques should

(d) Examination and testing of samples

(i) At least one test should be conducted on each lot of component drug product to verify identity

(ii) Each component must be tested for conformity with all appropriate written specifi cations for purity, strength, and quality if an ingredient or for conformity with written specifi cations for containers or closures (iii) In lieu of the above testing by the manufacturer, a report of analysis may be accepted from the supplier provided that at least one specifi c identity test is conducted on the component by the manufacturer and provided that the manufacturer has established the reliability of the supplier ’ s analyses through appropriate validation

(iv) When appropriate, components should be examined microscopically (v) Each lot of a component that is liable to contamination with dirt, insect infestation, or other extraneous adulterant should be examined against established specifi cations for such contamination

(vi) Each lot of a component that is subject to microbial contamination that

is contrary to its intended use should be subjected to microbiological tests before use

(e) If a lot of components meets the written specifi cations, it may be approved and released for use Any lot of such material that does not meet such speci-

fi cations must be rejected

4 Use of approved components (including drug product containers and closures) must be rotated to assure that the oldest approved stock is used fi rst

CURRENT GOOD MANUFACTURING PRACTICE 11

5 Components must be retested and/or reexamined after storage for a long period

of time or after exposure to the atmosphere, heat, or other condition that might adversely affect the component

6 Rejected components should be identifi ed and controlled under a quarantine system designed to prevent their use in manufacturing or processing

7 Containers and closures

(a) Containers and closures must not be reactive, additive, or absorbent so as to alter the drug beyond established acceptance criteria

(b) Container closure systems must provide adequate protection against able external factors in storage that can cause deterioration or contamination

steriliza-Production and Process Controls

1 Written procedures and procedure deviations

(a) Written procedures for production and process control must be written and followed These procedures should be designed to assure that the drug prod-ucts have the identity, strength, quality, and purity they are represented to possess These procedures must include all requirements given below and must be drafted, reviewed, and approved by the affected organizational units and reviewed and approved by the quality control unit

(b) When following the above identifi ed procedures, all actions must be mented at the time of performance Any deviations from the written proce-dure must be recorded and justifi ed

2 Charge - in of components — Written production and control procedures must include the following, which are designed to assure that the drug products pro-duced meet all specifi cations and standards

(a) The batch must be formulated with the intent to provide not less than 100%

of the labeled amount of active ingredient

(b) Components used must be weighed, measured, or subdivided appropriately

If a component is removed from its original container and placed in another, the new container should be identifi ed with the following information:

(i) Component name and/or item code

(ii) Receiving or control number

(iii) Weight or measure of material in the new container

(iv) Batch or lot number for which the component was dispensed, including its product name, strength, and lot number

(c) Weighing, measuring, or subdividing operations for all components must be adequately supervised Each container of component dispensed to manufac-turing must be examined by a second person to assure that:

(i) The component was released by the quality control unit

(ii) The weight or measure is correct as stated in the batch production records

12 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

(iii) The containers are properly identifi ed and contain the quantity stated

4 Equipment identifi cation

(a) All compounding and storage containers, processing lines, and major ment used during the production of a batch of a drug product must be prop-erly identifi ed at all times to indicate their contents and the phase of processing

equip-of the batch

(b) Major equipment should be identifi ed by a distinctive identifi cation that shall

be recorded in the batch production record to indicate the specifi c equipment used In cases where only one of a particular type of equipment exists in a given manufacturing facility, the name of the equipment may be used instead

of creating a distinctive identifi cation

5 Sampling and testing of in - process materials and drug products

(a) To assure batch uniformity and integrity, it is necessary to write and follow procedures that describe the in - process controls and tests or examinations that will be conducted on samples taken according to procedure Procedures should be written to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variabil-ity in the product being manufactured These control procedures should include but are not limited to the following:

(i) Tablet or capsule weight variation

(ii) Disintegraton time

(c) In - process materials should be tested for identity, strength, quality, and purity

as appropriate As a part of the production process, they must be approved for continued use or rejected by the quality control unit before production continues

(d) Rejected in - process materials must be identifi ed and controlled under a quarantine system designed to prevent their use in manufacturing operations for which they have been found to be unsuitable

6 When appropriate, time limits should be established for the completion of each phase of production The purpose of this is to assure the quality of the drug product Deviation from the established time limits may be acceptable if this deviation does not compromise the quality of the product Any deviation must

be documented, including the justifi cation for such deviation

CURRENT GOOD MANUFACTURING PRACTICE 13

7 Control of microbial contamination

required to be sterile, appropriate written procedures designed to prevent such growth should be written and followed

(b) If sterilization is a part of any procedure described in (a) above, this dure must be validated

8 Reprocessing

(a) Written procedures describing any system used to reprocess batches that do not conform to the established standards must be written and followed (b) Reprocessing must not be performed without the review and approval of the quality control unit

Packaging and Labeling Control

1 Materials examination and usage criteria

(a) Written procedures describing in detail the receipt, identifi cation, storage, handling, sampling, examination, and/or testing of labeling and packaging materials must be developed, approved, and followed These materials must

be representatively sampled, examined, or tested on receipt and accepted by the quality control unit before use

(b) Any materials that do not fully meet acceptance criteria must be rejected to prevent their use

(c) Records of each receival of each different label and packaging material must

be maintained indicating receipt, examination or testing, and whether accepted or rejected

(d) Labels and other labeling materials for each different drug product, strength, dosage form, or quantity of contents must be stored separately with suitable identifi cation Access to the storage area must be limited to authorized personnel

(e) Obsolete and outdated labels, labeling, and other packaging materials must

be quarantined and destroyed

strengths or different net contents is prohibited The only exception to this rule is if labels from gang - printed sheets are adequately differentiated by size, shape, or color that will prevent mixing of labels

(g) If cut labeling is used, packaging and labeling operations must include one

or more of the following special control procedures:

(i) Dedication of a labeling and packaging line to each different strength

of each different drug product

conduct a 100% examination for correct labeling during or after pletion of the fi nishing operation

(iii) Use of visual inspection to conduct a 100% examination for correct labeling If visual inspection is used, the inspection should be performed

by one person and independently verifi ed by a second individual (h) Printing devices on or associated with the manufacturing line used to imprint labeling upon the drug product unit label or case must be monitored to assure

14 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

that the printing conforms to the print specifi ed in the batch production record

fi nished and the amount of labeling issued if discrepancies outside narrow preset limits occur Limits should be established on the basis of historical operating data Labeling reconciliation is waived for either cut or roll label-ing if a 100% examination for correct labeling is performed

(d) All excess labeling bearing a lot or control number must be destroyed (e) Returned labeling should be maintained and stored in a manner to prevent mix - ups

(f) Written procedures should describe the control procedures used for the ance of labeling

3 There must be written procedures designed to assure that correct labels, labeling, and packaging materials are used These procedures should incorporate the fol-lowing features:

(a) Prevention of mix - ups and cross - contamination by physical or spatial tion of operations on other drug products

(b) Identifi cation and handling of fi lled drug product containers that are set aside and held in unlabeled condition for future labeling operations Such procedures should be designed to prevent mislabeling individual containers, lots, or portions of lots It is not necessary to apply identifi cation to each individual container, but the procedure should be adequate to determine the name, strength, quantity of contents, and lot or control number of each container

(c) Identifi cation of the drug product with a lot or control number that permits determination of the history of the manufacture and control of the batch (d) Examination of packaging and labeling materials for suitability and correct-ness before issuing for use and before packaging operations These examina-tions must be documented in the batch production record

(e) Inspection of the packaging and labeling facility immediately before use to assure that all drug products and labeling materials from the previous opera-tion have been removed Inspection results must be documented in the batch production record

4 Tamper - evident packaging requirements for OTC human drug products

(a) An OTC product (with the exception of a dermatological, dentifrice, insulin,

or lozenge product) intended for retail sale is considered adulterated or misbranded or both if it is not packaged in a tamper - resistant package (b) Requirements for a tamper - evident package

(i) With the exceptions listed above, all OTC products must be packaged

public while being held for sale A tamper - evident package must have

CURRENT GOOD MANUFACTURING PRACTICE 15

one or more indicators or barriers to entry which, if breached or missing, can reasonably be expected to provide visible evidence to consumers that tampering has occurred: A tamper - evident package may involve an immediate container and closure system or a secondary container or carton system or a combination of systems intended to provide a visual

designed to and shall remain intact when handled in a reasonable manner during manufacture, distribution, and retail display

(ii) In addition to the tamper - evident packaging feature described above, any two - piece hard gelatin capsule covered by this regulation must be produced using an acceptable tamper - evident technology

(c) Labeling

(i) In order to alert consumers to the specifi c tamper - evident features used, each retained package of an OTC drug product covered by this regula-tion is required to bear a statement that:

technologies

(2) Is prominently placed on the package

(3) Is so placed that it will be unaffected if the tamper - evident feature

of the package is breached or missing

(ii) If the tamper - evident feature chosen to meet the requirement uses an identifying characteristic, that characteristic is required to be referred

to in the labeling statement For example, the labeling statement on a

bottle with a shrink band could say For your protection, this bottle has

an imprinted seal around the neck

evident requirement A request for exemption is required to be submitted in the form of a petition and should be clearly identifi ed on the envelope as a “ Request for Exemption from the Tamper - Evident Packaging Rule ” This petition is required to contain the following:

(i) The name of the drug product or, if the petition seeks an exemption for

a drug class, the name of the drug class and a list of products within that class

(ii) The reasons that the drug product ’ s compliance with the tamper - evident packaging and labeling requirements is unnecessary or cannot be achieved

(iii) A description of alternative steps that are available or that the tioner has already taken to reduce the likelihood that the product or drug class will be the subject of malicious adulteration

(iv) Other information justifying an exemption

required to provide the FDA with notifi cation of changes in packaging and labeling to comply with the requirements of this section Changes in packag-ing and labeling required by the regulation may be made before FDA approval Manufacturing changes by which capsules are to be sealed require prior FDA approval

(f) This section does not affect any requirements for “ special packaging ” as required under the Poison Prevention Packaging Act of 1970

16 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

5 Drug product inspection

(a) Packaged and labeled products must be examined during fi nishing tions to provide assurance that containers and packages in the lot have the correct label

(b) A representative sample of units should be collected at the completion of

fi nishing operations and should be visually examined for correct labeling (c) Results of these examinations must be recorded in the batch production records

(d) Expiration dates must appear on labeling in accordance with the ments stated elsewhere in this regulation

(h) Pending consideration of a proposed exemption published in the Federal Register , September 29, 1978, the requirements in this section will not be

enforced for human drug products if their labeling does not bear dosage limitations and they are stable at least three years as supported by stability data

Holding and Distribution

(i) A procedure that assures the distribution of the oldest approved stock

fi rst Deviation from this procedure is acceptable if it is temporary and appropriate

CURRENT GOOD MANUFACTURING PRACTICE 17

(ii) A system for documenting distribution so that distribution of each lot

of drug product can be readily determined to facilitate its recall if required

Laboratory Controls

1 General requirements

(a) The establishment of any specifi cations, standards, sampling plans, test cesses, or other laboratory control mechanism required by this part of the regulation, including any changes to the above must be drafted by the appro-priate organizational unit and reviewed and approved by the quality control unit All actions must be documented at the time of performance and any deviation must be recorded and justifi ed

sound and appropriate specifi cations, standards, sampling plans, and test procedures designed to assure that all materials conform to appropriate standards of identity, strength, quality, and purity Laboratory controls should include:

(i) Determination of conformance to written specifi cations for the tance of each lot within each shipment of raw materials The specifi ca-tions should include a description of the sampling and testing procedures used Samples must be representative and adequately identifi ed These procedures must also require appropriate retesting of any material that

accep-is subject to deterioration

(ii) Determination of conformance to written specifi cations and a tion of sampling and testing procedures for in - process materials (iii) The calibration of instruments, apparatus, gauges, and recording devices

descrip-at specifi ed intervals in accordance with an established written program containing specifi c directions, schedules, limits for accuracy and preci-sion, and provisions for remedial action in the event that the limits are not met Any such devices that do not meet the established specifi ca-tions must not be used

2 Testing and release for distribution

(a) Laboratory testing of each lot of drug product must be conducted to establish conformance to fi nal specifi cations for the product Testing must include identity and strength of each active ingredient Where sterility and/or pyrogen testing are required on short - lived radiopharmaceuticals, batches may be released prior to completion of this testing provided that such testing is completed as soon as possible

(b) Each batch of product required to be free of objectionable microorganisms must be tested appropriately

(c) All sampling and testing plans must be described in written procedures that include the method of sampling and the number of units to be tested (d) Acceptance criteria for the sampling and testing conducted by the quality control unit must be adequate to assure that the batch being tested meets all specifi cations Appropriate statistical quality control criteria should be used The statistical quality control criteria must include acceptance levels and/or rejection levels

18 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

(e) The accuracy, sensitivity, specifi city, and reproducibility of test methods used must be established and documented Validation and documentation must

be accomplished in accordance with this regulation

(f) Drug products failing to meet established standards or specifi cations and any relevant quality control criteria must be rejected Reprocessing may be per-formed, however, prior to acceptance and use, and reprocessed material must meet all standards, specifi cations, and other relevant criteria

(ii) Storage conditions for sampled retained for testing

(iii) Reliable, meaningful and specifi c test methods

(iv) Testing of the product in the same container - closure system as the one

in which the product is to be marketed

(v) Testing of drug products for reconstitution at the time of dispensing as well as after they are reconstituted

(b) An adequate number of batches of each drug product must be tested to determine appropriate expiration date A record of such data must be main-tained Accelerated studies, combined with basic stability information on the components and drug product in its container - closure system may be used

to project a tentative expiration date that is beyond the date supported by shelf life studies However, there must be stability studies conducted includ-ing drug product testing at appropriate intervals until the tentative expiration date is verifi ed

(c) The requirements for homeopathic drug products are as follows:

(i) There must be a written assessment of stability based on testing or examination of the drug product for compatibility of the ingredients, and based on marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use

(ii) Evaluation of stability must be based on the same container - closure system as the one in which the drug product is to be marketed

(d) Allergenic extracts that are labeled “ No U.S Standard of Potency ” are exempt from the requirements of this section

4 Special testing requirements

free, there must be appropriate laboratory testing to establish conformance

to this claim The test procedures must be in writing and must be followed (b) For each batch of ophthalmic ointment, there must be appropriate testing to determine conformance to specifi cations regarding the presence of foreign particles and harsh or abrasive substances The test procedures must be in writing and must be followed

(c) For each batch of controlled - release dosage form, there must be appropriate laboratory testing to determine conformance to the specifi cations for the rate

CURRENT GOOD MANUFACTURING PRACTICE 19

of release of each active ingredient The test procedures must be in writing and must be followed

5 Reserve samples

(a) An identifi ed reserve sample that is representative of each lot or of each shipment of each active ingredient must be retained This reserve sample should contain at least twice the quantity needed for all tests required to determine whether the active ingredient meets its established specifi cations with the exception of sterility and pyrogen testing The required retention time is as follows:

(i) For an active ingredient in a drug product other than those described

in paragraphs (b) and (c) below, the reserve sample must be retained for one year after the expiration date of the last lot of drug product containing that lot of active ingredient

(b) For an active ingredient in a radioactive drug product except for tive reagent kits, the reserve sample must be retained for:

(i) Three months after the expiration date of the last lot of the drug product containing that lot of active ingredient if the expiration dating period

of the drug product is 30 days or less

(ii) Six months after the expiration date of the last lot of the drug product containing that lot of active ingredient if the expiration dating period

of the drug product is more than 30 days

(c) For an active ingredient in an OTC drug product that is exempt from bearing

an expiration date, the reserve sample must be retained for three years after distribution of the last lot of drug product containing that lot of active ingredient

(d) A properly identifi ed reserve sample that is representative of each batch

of drug product must be retained and stored under conditions consistent with the product labeling The reserve sample must be stored in the same immediate container closure system in which the drug product is marketed or in one that has essentially the same characteristics The reserve sample consists of at least twice the quantity needed to perform all the required tests except those for sterility and pyrogens Reserve samples from representative sample lots or batches selected by acceptable statistical procedures must be examined visually at least once a year for evidence of deterioration unless visual examination would affect the integrity of the reserve sample Any evidence of reserve sample deterioration must be investigated The results of the examination must be recorded and main-tained with stability data concerning that drug product Retention times are

as follows:

(i) For a drug product other than the exceptions noted above, the reserve sample must be retained for one year after the expiration date of the drug product

(ii) For a radioactive drug product, except for nonradioactive reagent kits, the retention sample must be retained for:

(1) three months after the expiration date of the drug product if the expiration date is 30 days or less or

(2) six months after the expiration date of the drug product if the ration date is more than 30 days

expi-20 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

(iii) For an OTC drug product that is exempt from bearing an expiration date, the reserve sample must be retained for three years after the batch

of drug product is fully distributed

6 Animals used in testing components, in - process materials, or drug products for compliance with established specifi cations must be maintained and controlled in

a manner that assures their suitability for their intended use They must be

identi-fi ed and adequate records must be maintained showing the history of their use

exposed to cross - contamination with penicillin, the nonpenicillin drug product must be tested for the presence of penicillin The drug product may not be marketed if a detectable level of penicillin is found when tested according to procedures specifi ed in “ Procedures for Detecting and Measuring Penicillin con-tamination in Drugs ” which is incorporated in the regulation by reference

Records and Reports

1 General Requirements

(a) Any production, control, or distribution record that is associated with a batch

of a drug must be retained for at least one year after the expiration date of the batch OR, for OTC drug products that do not have expiration dates, three years after complete distribution of the batch

(b) Records must be retained for all components, containers, closures, and ing for the same time periods shown in (a) above

(c) All retained records or copies of these records must be readily available for authorized inspection at any time in the required retention period Records must be available for inspection where the activities described therein occurred Photocopying or similar reproduction by investigators must be permitted

(d) Retained records may be original records or true copies such as photocopies, microfi lm, microfi che, or other accurate reproduction of the original (e) Written records that must be retained must be maintained so that data con-tained therein can be used for evaluating the quality standards of each drug product to determine the need for changes in drug product specifi cations or manufacturing or control procedures Such reviews should be conducted at least annually Written procedures must be established and followed for these evaluations and must include provisions for:

(i) A review of a representative number of batches, whether approved or rejected, and records associated with the batch

(ii) A review of complaints, recalls, returned or salvaged drug products, and investigations conducted under Section 211.192 of the GMP regulations for each drug product

(f) Procedures must be established to assure that the responsible offi cials of the

fi rm are notifi ed in writing of any investigations conducted under Sections 211.198, 211.204, or 211.208 of any recalls, reports of inspectional observa-tions issued by the FDA, or any regulatory actions relating to GMP brought

by the FDA

2 A written record of major equipment cleaning, maintenance (except routine maintenance), and use must be included in individual equipment logs that show

CURRENT GOOD MANUFACTURING PRACTICE 21

the date, time, product, and lot number of each batch processed The persons performing and double checking the cleaning and maintenance should date and sign or initial the log indicating that the work was performed Entries in the log must be in chronological order

3 Component, drug product container, closure, and labeling records must include the following:

(a) The identity and quantity of each shipment of each lot of components, drug product containers, closures, and labeling Also required are the identity of the supplier, the supplier ’ s lot number(s), the receiving code, the date of receipt, and name and location of the prime manufacturer if different from the supplier

(b) The results of any test or examination performed and any conclusions derived from these results

(c) An individual inventory record of each component and a reconciliation of the use of each lot of such component The inventory record must contain suffi cient information to allow determination of any batch or lot of drug product associated with the use of each component

(d) Documentation of the examination and review of labels and labeling for conformance with established specifi cations

(e) The disposition of rejected materials

4 Master production and control records

Batch production and control records should be prepared for each batch of drug product produced and must include complete information about the pro-duction and control of that batch These records must include:

(a) A full and complete reproduction of the appropriate master production or control record The copy must be checked for accuracy, dated, and signed (b) Documentation that each signifi cant step in the manufacture, processing, packaging, and holding of the batch was accomplished as prescribed, including:

(i) Dates

(ii) Identity of individual major equipment used This includes packaging lines

(iii) Complete and specifi c identifi cation of each batch of component or

in - process material used

processing

(v) In - process and laboratory control results

(vi) Inspection of the packaging and labeling area before and after use (vii) Documentation of the actual yield and the percentage of theoretical yield that this represents at critical stages of processing

(viii) Complete labeling control records, including specimens or copies of all labeling used

(ix) A description of drug product containers and closures

(x) Any sampling performed

(xi) Identifi cation of the persons performing and directly supervising or checking signifi cant steps in the operation

(xii) Any investigations conducted

(xiii) Results of examinations made

22 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

5 All drug product production and control records, including those for packaging and labeling, must be reviewed and approved by the quality control unit to deter-mine compliance with all established written procedures before a batch is released

or distributed Any unexplained discrepancy or the failure of a batch or any of its components to meet any of the established specifi cations must be thoroughly investigated The investigation must be extended to other batches of the same drug product and other drug products that may have been associated with the specifi c fault or discrepancy A written record of the investigation must be made and include the conclusions and any required follow - up

6 Laboratory records

(a) Laboratory records must include complete data derived from all tests needed

to assure compliance with established specifi cations and standards This includes examinations and assays as follows:

(i) A description of the sample received for testing with identifi cation of source For example, location where the sample was obtained, quantity, lot number or other distinctive code, date the sample was taken, and the date that it was received for testing

(ii) A statement of each method used in the testing of the sample The statement must indicate the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested (If the method used is in the current revision of the U.S Pharmacopeia (USP), National Formulary (NF), or other recognized standard reference or if it is detailed in an approved NDA, this statement will not be required.) (iii) A statement of the weight or measure of sample used for each test (iv) A complete record of all data secured in the course of each test, includ-ing all graphs, charts, and spectra from laboratory instrumentation properly identifi ed to the specifi c component and lot tested

(v) A record of all calculations performed in connection with the test, including units of measure, conversion factors, and equivalency factors

(vi) A statement of the results of tests and how the results compare with established standards of identity, strength, quality, and purity for the component tested

(vii) The initials or signature of the person who performed each test and the date the tests were performed

(viii) The initials or signature of a second person showing that the original records have been reviewed for accuracy, completeness, and compli-ance with established standards

(b) Complete records must be maintained of any modifi cation of an established method employed in testing These records must include the reason for the modifi cation and verify that the modifi cation produced results that are at least as accurate and reliable for the material being tested as the established method

(c) Complete records must be maintained of any testing and standardization of laboratory reference standards, reagents, and standard solutions

(d) Complete records must be maintained of the periodic calibration of tory instruments, apparatus, gauges, and recording devices

labora-CURRENT GOOD MANUFACTURING PRACTICE 23

(e) Complete records must be maintained of all stability testing performed in accordance with Section 211.166 of the regulation

7 Distribution records must contain the name and strength of the product and description of the dosage form, name and address of the consignee, date and quantity shipped, and lot or control number of drug product For compressed medical gas products, distribution records are not required to contain lot or control numbers

8 Complaint fi les

(a) Written procedures describing the handling of all written and oral complaints regarding a drug product must be established and followed These procedures must include provisions for review by the quality control unit of any com-plaint involving the possible failure of a drug product to meet any of its specifi cations and a determination as to the need for an investigation These procedures must include provisions for review to determine whether the complaint represents a serious and unexpected adverse drug experience which is required to be reported to the FDA

(b) A written record of each complaint must be maintained in a fi le designated for product complaints The fi le may be maintained at another facility if the written records of such fi les are readily available for inspection at that other facility Written reports involving a drug product must be maintained until

at least one year after the expiration date of the drug product or one year after the date that the complaint was received, whichever is longer In the case of certain OTC drug products lacking expiration dating because they meet the criteria for exemption, such written records must be maintained for three years after distribution of the drug product

where known: the name and strength of the drug product, lot number, name of complainant, nature or complaint, and reply to the complainant

(ii) Where an investigation is conducted, the written record must include the fi ndings of the investigation and follow - up The record or a copy

of the record of investigation must be maintained at the location where the investigation occurred

(iii) Where an investigation is not conducted, the written record must include the reason that an investigation was not considered to be necessary and the name of the responsible person making the determination

Returned and Salvaged Drug Products

1 Returned drug products — Returned drug products must be identifi ed as such and held If the conditions under which returned drug products have been held, stored, or shipped before or during the return or the condition of the drug product, its container, carton, or labeling is a result of storage or shipping casts doubt on the safety, identity, strength, quality, or purity of the drug product, the returned drug product must be destroyed unless examination testing or other investigation proves the drug product meets appropriate standards Records of returned drug products must be maintained and must include the name and label potency of the drug

24 GOOD MANUFACTURING PRACTICES & RELATED FDA GUIDELINES

product dosage lot number, reason for the return, quantity returned, date of tion, and ultimate disposition of the returned product If the reason for a drug product being returned implicates associated batches, an investigation must be conducted Procedures for the holding, testing, and reprocessing of returned drug products must be in writing and must be followed

2 Drug product salvaging — Drug products that have been subjected to improper storage conditions, including extremes in temperature, humidity, smoke, fumes, pres-sure, age, or radiation due to natural disasters, fi res, accidents, or equipment failures, must not be salvaged and returned to the marketplace Whenever there is a question whether drug products have been subjected to such conditions, salvaging operations may be conducted only if there is (a) evidence from laboratory tests and assays that the drug products meet all applicable standards of identity, strength, quality, and purity and (b) evidence from inspection of the premises that the drug products and associated packaging were not subjected to improper storage conditions as a result

of the disaster or accident Organoleptic examinations are acceptable only as plemental evidence that the drug products meet appropriate standards of identity, strength, quality, and purity Records including name, lot number, and disposition must be maintained for drug products subject to this section

1.1.3 GUIDANCE FOR INDUSTRY: QUALITY SYSTEMS APPROACH

TO PHARMACEUTICAL CURRENT GOOD MANUFACTURING

PRACTICE REGULATIONS

This guidance document was written by the FDA to help manufacturers implement what they consider to be modern quality systems and risk management approaches

describes what the FDA considers a comprehensive quality systems (QS) model It also explains how manufacturers can be in full compliance with the GMP regula-tions by implementing such quality systems The FDA does not intend this guidance

to place new expectations on manufacturers nor does this replace the GMPs

As is true with all guidance documents, this document does not establish legally enforceable responsibilities, but rather it describes the FDA ’ s current thinking Thus, this guidance should be viewed as a set of recommendations unless a regulation is cited

The objective of this guidance is to describe a quality systems model and onstrate how and where the elements of this model can fi t within the requirements

dem-of the CGMP regulations The philosophy being put forward is that quality should

be build into the product, and testing alone cannot be relied on to ensure product quality

1.1.3.1 CGMPS and the Concepts of Modern Quality Systems

The FDA believes that several key concepts are critical for any discussion of modern quality systems The following concepts are used throughout this guidance as they relate to the manufacture of pharmaceutical dosage forms: